This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ModivCare (MODV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -103.70% and 0.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Agilon Health (AGL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of 0% and 4.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -145% and 2.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Surges 17.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alignment Healthcare (ALHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ModivCare (MODV) Misses Q2 Earnings Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -2.65% and 7.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Misses Q1 Earnings Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -4.05% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 35.26% and 6.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 8.36% and 5.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 6.62% and 9.98%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing ModivCare (MODV) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy AMN Healthcare Services (AMN) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Top Ranked Stocks for Exposure to the Medical Sector
by Shaun Pruitt
The healthcare business offers attractive defensive attributes that are so valuable in the current uncertain environment. As such, adding healthcare stocks to the portfolio brings much needed diversification.
Zacks Industry Outlook Highlights HealthEquity, AMN Healthcare and ModivCare
by Zacks Equity Research
HealthEquity, AMN Healthcare and ModivCare have been highlighted in this Industry Outlook article.
3 Medical Services Stocks Braving Near-Term Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, AMN and MODV are set to gain the most. However, staffing shortages may disrupt the trend.
MODV vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. PGNY: Which Stock Is the Better Value Option?
Zacks.com featured highlights include BorgWarner Univar Solutions, Marathon Petroleum, Barclays and ModivCare
by Zacks Equity Research
BorgWarner, Univar Solutions, Marathon Petroleum, Barclays and ModivCare are part of Zacks Screen of the Week article.
5 Best Value Stocks Based on Discounted PEG Ratio
by Urmimala Biswas
Here are five stocks, BWA, UNVR, MPC, BCS and MODV, which qualify our value-based screening criteria.
Can ModivCare (MODV) Climb 29% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 28.5% upside potential for ModivCare (MODV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MODV vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MODV vs. PGNY: Which Stock Is the Better Value Option?
Best Momentum Stocks to Buy for August 10th
by Zacks Equity Research
TTMI, CIGI and MODV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 10, 2022.
Does ModivCare (MODV) Have the Potential to Rally 32% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for ModivCare (MODV) points to a 31.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ModivCare (MODV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 39.16% and 7.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Surges 6.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Doximity (DOCS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ModivCare (MODV) Q1 Earnings Lag Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -0.63% and 1.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ModivCare (MODV) Q1 Earnings Expected to Decline
by Zacks Equity Research
ModivCare (MODV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.